TLR4 and Sepsis: Several studies in experimental model of sepsis have also shown that simvastatin improved survival, attenuated activation of stress-activated protein kinase JNK/SAPK and apoptosis in liver and spleen (Shinozaki et al., 2010), reduced cardiomyocyte apoptosis through decreased p53 expression (Buerke et al., 2008), and mitigated lung tissue injury by inhibiting toll-like receptor 4 (TLR4)/NF-κB signaling pathway and expression of caspase-3 and Bax (Wang et al., 2018).